Search research articles
Contact Us
Filters
Showing results (41-50 of 107) with videos related to
Page
of 11
Sort By:
Cancer Treatment Reports
|
July 1, 1984
Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone
N Tannir, H Y Yap, G H Hortobagyi, et al.
Cancer
|
July 15, 1982
Treatment for meningeal carcinomatosis in breast cancer
H Y Yap, B S Yap, S Rasmussen, et al.
Seminars in Oncology
|
September 1, 1984
Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer
F A Holmes, H Y Yap, L Esparza, et al.
Cancer Treatment Reports
|
July 1, 1982
Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene)
B S Yap, H Y Yap, G R Blumenschein, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 1, 1983
Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy
G N Hortobagyi, W Spanos, E D Montague, et al.
Cancer
|
January 1, 1984
Carminomycin. A new anthracycline analog in the treatment of advanced breast cancer
A Aboud, H Y Yap, L Esparza, et al.
Cancer Treatment Reports
|
September 1, 1981
Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion
H Y Yap, G R Blumenschein, G P Bodey, et al.
Annals of Internal Medicine
|
December 1, 1981
Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer
H Y Yap, G R Blumenschein, F C Schell, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1986
A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer
F A Holmes, L Esparza, H Y Yap, et al.
Scientific Reports
|
July 19, 2022
Activation function 1 of progesterone receptor is required for mammary development and regulation of RANKL during pregnancy
Shi Hao Lee, Yeannie H Y Yap, Chew Leng Lim, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 107) with videos related to
Sort By:
Page
of 11
Cancer Treatment Reports
|
July 1, 1984
Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone
N Tannir, H Y Yap, G H Hortobagyi, et al.
Cancer
|
July 15, 1982
Treatment for meningeal carcinomatosis in breast cancer
H Y Yap, B S Yap, S Rasmussen, et al.
Seminars in Oncology
|
September 1, 1984
Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer
F A Holmes, H Y Yap, L Esparza, et al.
Cancer Treatment Reports
|
July 1, 1982
Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene)
B S Yap, H Y Yap, G R Blumenschein, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 1, 1983
Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy
G N Hortobagyi, W Spanos, E D Montague, et al.
Cancer
|
January 1, 1984
Carminomycin. A new anthracycline analog in the treatment of advanced breast cancer
A Aboud, H Y Yap, L Esparza, et al.
Cancer Treatment Reports
|
September 1, 1981
Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion
H Y Yap, G R Blumenschein, G P Bodey, et al.
Annals of Internal Medicine
|
December 1, 1981
Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer
H Y Yap, G R Blumenschein, F C Schell, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1986
A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer
F A Holmes, L Esparza, H Y Yap, et al.
Scientific Reports
|
July 19, 2022
Activation function 1 of progesterone receptor is required for mammary development and regulation of RANKL during pregnancy
Shi Hao Lee, Yeannie H Y Yap, Chew Leng Lim, et al.
Page
of 11